MUC16 and pancreatic neoplasm: Multi-biomarker dynamic monitoring provides precise assessment tools for personalized treatment.Exploratory analyses of other tumor markers (CEA, CA125, AFP) were conducted based on two considerations: first, their potential complementary value to CA19-9, as CA19–9 is unreliable in Lewis-negative patients (49), and CEA/CA125 have been reported to aid in differentiating pancreatic cancer from other gastrointestinal tumors (50, 51); second, preliminary evidence suggesting CA125 may correlate with PFS in some gastrointestinal malignancies (29, 51).